Targeting the Tie-2 Receptor with Faricimab in Central Serous Chorioretinopathy: A Case Series Motivated by a Genetic Finding-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Targeting the Tie-2 Receptor with Faricimab in Central Serous Chorioretinopathy: A Case Series Motivated by a Genetic Finding

Published:2024-09 Issue: Volume: Page:
ISSN:0002-9394
Container-title:American Journal of Ophthalmology
language:en
Short-container-title:American Journal of Ophthalmology

Author:

Rämö Joel T,Kim Leo A,Stryjewski Tomasz,Shah Priya P,Bejjani Romy,Brodie Frank L.,Eliott Dean,Sobrin Lucia,Vavvas Demetrios G,Rossi Elizabeth J

Funder

National Institutes of Health

Massachusetts Eye and Ear

Publisher

Elsevier BV

Reference29 articles.

1. Central serous chorioretinopathy in younger and older adults;Spaide;Ophthalmology,1996

2. Optical coherence tomography characterisation of idiopathic central serous chorioretinopathy;Montero;Br J Ophthalmol,2005

3. Long-term Visual Outcomes and Causes of Vision Loss in Chronic Central Serous Chorioretinopathy;Mrejen;Ophthalmology,2019

4. Half-dose verteporfin photodynamic therapy for acute central serous chorioretinopathy: one-year results of a randomized controlled trial;Chan;Ophthalmology,2008

5. Lack of positive effect of intravitreal bevacizumab in central serous chorioretinopathy: meta-analysis and review;Chung;Eye,2013

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP